[Treatment of impetiginized eczema with prednicarbate in combination with a quarternary ammonium salt].
After a brief account of the therapeutic problems with microbially superinfected eczemas, the results of a double-blind study of hospitalized patients are reported. Two concentrations of the antibacterial agent Bardac-22 (didecyl-dimethyl-ammonium chloride. Hoe S 2922) in combination with the steroid prednicarbate (prednisolone 17-(ethylcarbonate)-21-propionate, Hoe 777) were used. The quantitative determination of cutaneous bacteria was performed by a modified method of Faergemann. The double blind study did not reveal any significant differences in effectiveness, although a trend in favour of the higher concentration was apparent.
D000891:Anti-Infective Agents, Local / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004485:Eczema / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007169:Impetigo / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000644:Quaternary Ammonium Compounds / Q000627:therapeutic use*
D000891:Anti-Infective Agents, Local; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000644:Quaternary Ammonium Compounds; D011239:Prednisolone; C035287:prednicarbate; C027118:didecyldimethylammonium
Zur Behandlung des impetiginisierten Ekzems mit Prednicarbat in Kombination mit einem quarternären Ammoniumsalz.